Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. Additionally we are shipping VHL Kits (7) and VHL Proteins (7) and many more products for this protein.
Showing 10 out of 111 products:
Human Monoclonal VHL Primary Antibody for IHC (f), IP - ABIN967508
Baba, Hirai, Kawakami, Kishida, Sakai, Kaneko, Yao, Shuin, Kubota, Hosaka, Ohno: Tumor suppressor protein VHL is induced at high cell density and mediates contact inhibition of cell growth. in Oncogene 2001
Show all 7 references for ABIN967508
Human Monoclonal VHL Primary Antibody for ELISA, WB - ABIN393528
Peña, Lathia, Shan, Escudier, Bukowski: Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. in Clinical cancer research : an official journal of the American Association for Cancer Research 2010
Show all 5 references for ABIN393528
Human Monoclonal VHL Primary Antibody for IHC (fro), IHC (p) - ABIN264443
Los, Jansen, Kaelin, Lips, Blijham, Voest: Expression pattern of the von Hippel-Lindau protein in human tissues. in Laboratory investigation; a journal of technical methods and pathology 1996
Show all 4 references for ABIN264443
Human Polyclonal VHL Primary Antibody for EIA, WB - ABIN453458
Olmos, Arenas, Bienes, Calzada, Aragonés, Garcia-Bermejo, Landazuri, Lucio-Cazaña: 15-Deoxy-Delta(12,14)-prostaglandin-J(2) reveals a new pVHL-independent, lysosomal-dependent mechanism of HIF-1alpha degradation. in Cellular and molecular life sciences : CMLS 2009
Show all 3 references for ABIN453458
Human Polyclonal VHL Primary Antibody for EIA, WB - ABIN453457
Hatzimichael, Dranitsaris, Dasoula, Benetatos, Stebbing, Crook, Bourantas: Von Hippel-Lindau methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease. in Clinical lymphoma & myeloma 2009
Show all 3 references for ABIN453457
Human Polyclonal VHL Primary Antibody for ELISA, WB - ABIN185675
Kong, Lin, Liang, Fath, Sang, Caro: Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. in Molecular and cellular biology 2006
Human Polyclonal VHL Primary Antibody for IHC, ELISA - ABIN1533202
Latif, Tory, Gnarra, Yao, Duh, Orcutt, Stackhouse, Kuzmin, Modi, Geil: Identification of the von Hippel-Lindau disease tumor suppressor gene. in Science (New York, N.Y.) 1993
Human Monoclonal VHL Primary Antibody for EIA, IHC (p) - ABIN121157
Staller, Sulitkova, Lisztwan, Moch, Oakeley, Krek: Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. in Nature 2003
Loss of Vhl in mesenchymal progenitors of the limb bud caused severe fibrosis of the synovial joints and formation of aggressive masses with histologic features of mesenchymal tumors.
These data suggested that intestinal epithelial cells were injured after IM treatment through the pVHL overexpression-induced degradation of collagen I or HIF-1alpha (show HIF1A Antibodies).
Vhl and Kif3a (show KIF3A Antibodies) deletion accelerates renal cyst formation
maintains the stability and suppressive function of Foxp3 (show FOXP3 Antibodies)+ T cells via regulation of HIF-1a (show HIF1A Antibodies) pathway
Deletion of the Vhl gene causes sympathoadrenal cell death and impairs chemoreceptor-mediated adaptation to hypoxia.
Molecular dynamics of hif-1alpha (show HIF1A Antibodies) and VHL may determine the success of antineoplastic strategies in hypoxia-reoxygenation as predicted by computational modeling.
Loss of Vhl in adult joint cartilage is associated with earlier dysregulation of cartilage homeostasis, characterized by increased chondrocyte apoptosis, compromised chondrocyte autophagy and accelerated age-related and surgery-induced OA development.
Both Vhl and Bap1 (show BAP1 Antibodies) are required for kidney function. Even when Vhl is inactivated in multipotent nephron progenitor cells, Vhl loss is insufficient for renal tumorigenesis.
VHL deficiency perturbs pancreas endocrine homeostasis in mice.
data suggest that the VHL-mediated signaling in osteochondral progenitor cells plays a critical role in bone remodeling at postnatal/adult stages through coupling osteogenesis and angiogenesis
HBV induces the HIF2alpha (show EPAS1 Antibodies) expression through its encoded protein HBx. This upregulates the HIF-2alpha (show EPAS1 Antibodies) expression by binding to the pVHL activating the NF-kappaB (show NFKB1 Antibodies) signaling pathway
inhibition of miR566 expression increases the expression levels of VHL, decreases the expression levels of VEGF, and inhibits the invasive and migratory abilities of glioblastoma.
proteome and phospho-proteomic analysis of isogenic 786-O renal cell carcinoma (show MOK Antibodies) (+/-VHL) cells to compare signatures that reflect hypoxia and/or loss of VHL protein
Pars (show EPRS Antibodies) plana vitrectomy in advanced VHL eye disease can improve or preserve visual function, but postoperative progression of ocular VHL disease can be accelerated in cases where retinotomy is performed.
AR-suppressed miRNA-145 is a key player in renal cell carcinoma (show MOK Antibodies) progression by regulating HIF2alpha (show EPAS1 Antibodies)/VEGF (show VEGFA Antibodies)/MMP9 (show MMP9 Antibodies)/CCND1 (show CCND1 Antibodies) expression levels, irrespective of VHL status.
VHL was shown to influence cellular metabolism through its effect on HIF proteins as well as by affecting activity of other factors.
Data indicate that mutant VHL can protect HIF1alpha (show HIF1A Antibodies) from SART1 (show SART1 Antibodies)-dependent degradation in normoxic conditions, but this protection is lost in hypoxic settings, favoring hypoxia-dependent ccRCC proliferation.
VHLp19 has a role for regulating EPO (show EPO Antibodies) levels that VHLp30 does not have, whereas VHLp30 is really the tumor suppressor isoform.
pVHL interacts with CERKL (show CERKL Antibodies) and ubiquitinates it for oxygen dependent proteasomal degradation.
APOE (show APOE Antibodies), VHL and MTHFR (show MTHFR Antibodies) gene polymorphisms were related to the risk of renal cell carcinoma (show MOK Antibodies)
Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.
, von Hippel-Lindau disease tumor suppressor
, von Hippel-Lindau syndrome homolog
, von Hippel-Lindau syndrome protein homolog
, elongin binding protein
, protein G7